Author

Emily Leblond

Institution: Theradex Oncology (United States)

Observed institution: Theradex Oncology (United States)

OpenAlex ID: A5054115368

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

2018 · Scott F Huntington, Stephen J. Schuster, et al. · Blood · 2

Works count: 1

Citation count: 2

H-index: 1

I10-index: